Novilytic, an innovator in molecular recognition technology, is proud to announce an exclusive distribution partnership with Avantor, a global supplier of discovery-to-delivery solutions and the parent company of VWR.

Effective immediately, this strategic partnership will make Novilytic’s Proteometer® platform – including the Proteometer-L, Proteometer-UFT, and the upcoming Proteometer-CV readily accessible to laboratories across the United States, Europe Union, and United Kingdom. Leveraging Avantor’s extensive distribution network, this collaboration represents a shared commitment to driving innovation and efficiency in pharmaceutical research.

“Sample preparation has long been a bottleneck in pharmaceutical research. Every time you touch a sample, you risk compromising it,” said Robert Fitzgerald, Manager of Avantor’s Chromatography Portfolio. “The beauty of Novilytic’s Proteometer is that it removes that step entirely. It’s a groundbreaking innovation developed by Dr. Fred Regnier and his brilliant team, yet it is intuitive enough for anyone to use. The Proteometer is a game-changer, and we are thrilled to bring it to our global customer base.”

 “This partnership represents a significant milestone for Novilytic as we scale the impact of our groundbreaking Proteometer platform, said Paul Dreier, CEO of Novilytic. By combining our innovative technology with Avantor’s unmatched distribution network, we are setting a new standard for efficiency and reliability in drug discovery, clone selection, and more. Our shared mission is to eliminate inefficiencies in drug development and positively transform patient outcomes worldwide.”